Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Tuberculosis and HIV news

Show

From To
WHO interim guidance on the use of delamanid in the treatment of MDR-TB

A new TB drug with a novel mechanism of action – delamanid - is now available for treatment of adults with multidrug-resistant tuberculosis (MDR-TB). Delamanid was granted conditional approval by the European Medicine Agency in April 2014. Information about this new drug however remains limited, since it has only been through Phase IIb trial and studies for safety and efficacy. WHO is therefore issuing “interim policy guidance” that lists five conditions that must be in place if delamanid is used to treat adults with MDR-TB

Published
29 October 2014
From
World Health Organization
Success short treatment against drug-resistant tuberculosis confirmed

In what has become known as the Bangladesh regimen, ITM’s Armand Van Deun and colleagues developed a treatment of only 9 months. This regimen replaces the currently recommended treatment of 18 to 24 months. In 2010, the researchers reported that this treatment increased the success rate from 65% to 88% for MDR-TB patients in Bangladesh. The treatment is based on a combination of existing drugs.The researchers report a favourable outcome in roughly 85% of cases, in spite of increasing levels of serious second-line drug resistance. A smaller study in Niger confirmed the outstanding results of the shorter treatment.

Published
28 October 2014
From
Institute of Tropical Medicine
UNITAID’s EXPAND-TB and TBXpert MTB-RIF Projects Detect Over A Quarter of all MDR-TB Cases

UNITAID welcomes new data in the World Health Organization’s new global report on tuberculosis (TB) which shows a 30% increase in case detection of multi-drug resistant TB (MDR-TB) in 2013, much of which is attributed to the roll out of the UNITAID-funded EXPAND-TB and TBXpert projects. UNITAID’s EXPAND-TB project enabled the installation of sophisticated testing platform technology in TB reference laboratories across 27 countries, bearing 40% of the MDR-TB burden. This provided the capability to detect MDR-TB for the first time for many countries.

Published
27 October 2014
From
UNITAID
TB Alliance Launches Phase 2B Clinical Trial of a Novel TB Drug Regimen that Could Cut Treatment Time by Half or More for a Majority of TB Patients

NC-005 trial tests a novel regimen of bedaquiline (Sirturo), pretomanid (formerly known as PA-824), and pyrazinamide; results could pave the way for a three-month TB treatment.

Published
27 October 2014
From
TB Alliance
WHO report shows progress on HIV-associated TB but pace needs to be faster

The Global Tuberculosis Report 2014 highlights that while the number of TB deaths among people living with HIV has been falling for almost a decade—from 540 000 in 2004 to 360 000 in 2013—early case detection, antiretroviral treatment, preventive therapy and other key activities need to be further scaled-up.

Published
27 October 2014
From
UNAIDS
Bedaquiline as part of tailored therapy for MDR- and XDR-TB achieves impressive culture conversion rates

Use of the new anti-tuberculosis (TB) drug bedaquiline as part of a tailored regimen achieved high rates of culture conversion in people with multidrug-resistant TB (MDR-TB) and extensively

Published
27 October 2014
By
Michael Carter
'Nine million have TB' - WHO report

The World Health Organization revises its estimate as to how many people have tuberculosis up by 500,000, in its latest report into the killer disease.

Published
22 October 2014
From
BBC Health
Drug-resistant tuberculosis poses global threat, warn doctors

World Health Organisation says spread of hardier strains of TB across former USSR nations is of ‘critical concern’.

Published
22 October 2014
From
The Guardian
2014 Report on Tuberculosis Research Funding Trends, 2005–2013

Worldwide, governments, foundations, and companies invested US$676.7 million in research to develop new drugs, vaccines, and diagnostics against tuberculosis (TB) in 2013—barely one-third of the US$2 billion that experts estimate the world must spend each year to end the global TB epidemic—according to an analysis released today by Treatment Action Group (TAG).

Published
22 October 2014
From
TAG
South Africa: Bedaquiline approved to treat multi-drug resistant tuberculosis

The Medicines Control Council has approved Janssen Pharmaceutica's bedaquiline, the first drug specifically designed for treating multi-drug resistant tuberculosis (MDR-TB) to reach the market. Janssen is a subsidiary of Johnson & Johnson.

Published
21 October 2014
From
Business Day

Filter by country